INTRODUCTION
============

Amongst the major factors which regulate arterial pressure are the vasodilator, nitric oxide (NO), and the vasoconstrictor, endothelin (ET)-1 ([@B23]; [@B7]). Pressure regulation by NO and ET-1 is complex and extends beyond their individual depressor and pressor actions, respectively, due to the numerous interactions between NO and ET-1. These interactions include (1) ET-1 release of NO from the vascular endothelium, mediated by endothelial ET~B~ receptors; (2) NO inhibition of contraction to ET-1, the contraction mediated by ET~A~ and/or ET~B~ receptors ([@B31]), and (3) NO inhibition of ET-1 formation/release ([@B23]; [@B7]).

Not unexpectedly, the relative roles of these different ET-1-NO interactive mechanisms in the regulation of arterial pressure are not entirely clear due to the difficulty in the differentiation of the ET-1-NO interactions *in vivo*. In fact, these mechanisms are largely delineated *ex vivo* and, moreover, through the use of NO donors and exogenous ET-1 both *ex* *vivo* and *in vivo* ([@B23]; [@B7]).

Although not directly addressing the differential involvement of these mechanisms in the elevation of arterial pressure, acute challenge with NO synthase (NOS) inhibitors present a unique opportunity for the assessment of the overall importance of endogenous NO in the modulation of the ET-1-mediated drive to elevate arterial pressure. That is, a component of the NOS inhibitor-elevation of arterial pressure is ET-1-mediated, as determined with ET receptor antagonists and an ET converting enzyme inhibitor (for reviews which incorporated this subject see [@B23]; [@B7]).

Thus, we presently consider that (1) a detailed examination of the characteristics of the ET-1-dependent, elevated pressure due to acute challenge with NOS inhibitor may provide an *in vivo* context for mechanistic studies directed toward uncovering the intertwined NO and ET-1 pathways in the regulation of arterial pressure and (2) these characteristics would likely provide insight into the vascular pathophysiology resulting from NO dysregulation.

ET-1 AND PRESSURE ELEVATED BY ACUTE NOS INHIBITOR
=================================================

ET CONVERTING ENZYME INHIBITION
-------------------------------

Phosphoramidon, an ET converting enzyme inhibitor, variably lowered the NOS inhibitor-elevated pressure ([@B28]; [@B30]; [@B18]; **Figure [1](#F1){ref-type="fig"}**). The relative magnitude of the phosphoramidon-sensitive to -insensitive component ranged from approximately half to nearly the total pressure elevated by NOS inhibitor, as determined in rabbit and rat ([@B28]; [@B30]; [@B18]; **Figure [1](#F1){ref-type="fig"}**). This variability was not due to different efficacies of phosphoramidon inhibition of ET converting enzyme in these studies since (a) in rabbit, intraventricular 10 mg/kg phosphoramidon reduced by 88% big ET-1-elevated arterial pressure ([@B18]). Moreover, the considerable phosphoramidon inhibition of the elevated pressure due to big ET-1 occurred even though big ET-1 increased pressure by 57 mmHg in comparison to the NOS inhibitor-elevated pressure of only 17 mmHg ([@B18]); (b) in rat, the phosphoramidon doses (intravenous 10 and 15 mg/kg/h; [@B28]; [@B30], respectively) were similar to those used in another rat study in which the big ET-1-elevated arterial pressure was abolished ([@B29]). Basal arterial pressure was also not a factor in the phosphoramidon reduction of the NOS inhibitor-elevated elevated pressure since basal pressure was not lowered by phosphoramidon ([@B28]; [@B30]; [@B18]; **Figure [1](#F1){ref-type="fig"}**).

![**Effects of ET converting enzyme inhibitor and ET receptor antagonist on basal and NOS inhibitor-elevated arterial pressure.** MAP = mean arterial pressure and ET~A~, ET~B~, and ET~A/B~ = ET type A, type B, and A plus B receptor antagonists, respectively. ↑, ↓, -, n.d., and n.r. signify increased, decreased, no change, not determined, and not reported, respectively. Dashed arrow and broken dash represent the directional change and lack of change, respectively, in NOS inhibitor-elevated pressure by ET receptor antagonist as compared to NOS inhibitor-elevated basal pressure in the absence of ET receptor antagonist. Percent inhibitions shown represent reported values or, if not reported, were estimates. [@B14] utilized stroke-prone spontaneously hypertensive rat.](fphar-05-00057-g001){#F1}

ET RECEPTOR ANTAGONISM
----------------------

### ET~**A**~ and ET~**A/B**~ receptor antagonist

ET~A~ and ET~A/B~ receptor antagonist also reduced NOS inhibitor-elevated pressure ([@B30]; [@B32]; [@B35]; [@B3]; [@B15]; [@B13]; [@B16]; [@B18]; [@B14]; [@B19]; [@B26]; [@B36]; [@B27]; [@B22]; [@B33]; [@B17]; [@B21]; [@B25]; [@B6]; [@B10]; [@B11]; [@B8]; [@B9]; **Figure [1](#F1){ref-type="fig"}**). In a large majority of these studies the reduced NOS inhibitor-elevated pressure occurred in the absence of decreased basal pressure due to ET~A~/ET~A/B~ receptor antagonist ([@B30]; [@B32]; [@B35]; [@B3]; [@B13]; [@B16]; [@B18]; [@B14]; [@B36]; [@B27]; [@B33]; [@B21]; [@B6]; **Figure [1](#F1){ref-type="fig"}**), while in several studies ET~A~/ET~A/B~ receptor antagonist decreased basal pressure ([@B19]; [@B22]; [@B17]; [@B25]; [@B11]; **Figure [1](#F1){ref-type="fig"}**). The relative magnitudes of the ET~A~/ET~A/B~ receptor antagonist-sensitive component of the NOS inhibitor-elevated pressure also varied greatly, ranging from 0 to 100% ([@B30]; [@B32]; [@B35]; [@B3]; [@B13]; [@B16]; [@B18]; [@B14]; [@B36]; [@B27]; [@B33]; [@B17]; [@B21]; [@B6]; [@B10]; [@B9]; **Figure [1](#F1){ref-type="fig"}**). The variability was not due to the use of:

\(a\) ET~A~ versus ET~A/B~ receptor antagonist, since both ET~A~ and ET~A/B~ receptor antagonist reduced the NOS inhibitor-elevated pressure to similar magnitudes ([@B32]; [@B13]; [@B8]). Furthermore, ET~A/B~ receptor antagonist was less efficacious than ET~A~ receptor antagonist in dog ([@B26]; [@B36]). While the greater inhibitory efficacy of ET~A~ as compared to ET~A/B~ receptor antagonist ([@B26]; [@B36]) is not entirely clear, one possible explanation is that ET~B~ receptor antagonism may cause additional effects that limit the overall ET~A~ receptor reduction of the NOS inhibitor-elevated pressure.

It should be also be noted, however, that there is some limited evidence that non-selective ET receptor antagonism is required to fully expose the ET-1-dependent component of the NOS-I-elevated pressure. In rat, 10 mg/kg BQ123 (ET~A~ receptor antagonist) did not decrease the NOS inhibitor-elevated pressure while 10 mg/kg SB209670 (ET~A/B~ receptor antagonist) inhibited the elevation by 56% ([@B16]). These findings raise the possibility that smooth muscle ET~B~ receptors also mediate the elevated arterial pressure, presumably through ET-1-induced vasoconstriction. It may also be considered that cross-talk between the ET~A~ and ET~B~ receptors ([@B31]) is responsible for the greater inhibitory effect of ET~A/B~ versus ET~A~ receptor antagonist ([@B16]).

\(b\) Different species, since amongst dog and rat studies the reductions of the NOS inhibitor-elevated pressure by ET~A/B~ receptor antagonists both ranged considerably, i.e., from 0 to 100% ([@B36]; [@B17]; [@B21]; [@B6]) and 23--67% ([@B30]; [@B32]; [@B3]; [@B13]; [@B16]; [@B14]), respectively (**Figure [1](#F1){ref-type="fig"}**).

\(c\) Conscious versus anesthetized animals, since in conscious and anesthetized rat, ET~A/B~ receptor antagonist decreased NOS inhibitor-elevated arterial pressure by 23--67% ([@B30]; [@B3]; [@B13]; [@B16]) and by 40% and 49% ([@B32]; [@B14]), respectively (**Figure [1](#F1){ref-type="fig"}**).

\(d\) Different doses of ET receptor antagonist, since ET receptor antagonist doses were generally highly efficacious. Specifically, in several studies in which the effects of ET receptor antagonist on both NOS inhibitor and exogenous ET-1- and big ET-1-elevated pressure were examined, the ET receptor antagonist greatly inhibited the elevated pressure due to ET-1/big ET-1 even though the ET-1/big ET-1 dose generally induced a greater increase in pressure than the NOS inhibitor ([@B35]; [@B13]; [@B18]; [@B14]; [@B21]; [@B6]). However, an untested (to our knowledge) assumption underlying this comparative analysis of the inhibitory efficacy of ET receptor antagonist toward the NOS inhibitor- and ET-1-/big ET-1-elevated pressure is whether ET receptor antagonist efficacy is reduced by cellular events associated with NOS inhibition.

The possibility that in some studies the dose of ET receptor antagonist lacked sufficient efficacy should also be considered. For example, 2 mg/kg BQ123 failed to reduce the NOS inhibitor-elevated pressure in mouse ([@B9]). Whether a greater BQ123 dose would have reduced the NOS inhibitor-elevated pressure ([@B9]) remains a possibility since in rabbit, in which the NOS inhibitor-elevated pressure peaked and then decreased somewhat to a maintained level, 10 mg/kg but not 1 mg/kg BQ123 reduced the peak pressure elevation ([@B18]). Also, in rat 10 mg/kg BQ123 failed to reduce the NOS inhibitor-elevated pressure ([@B16]), although in another study 3 mg/kg BQ123 decreased the elevated pressure by 49% ([@B32]).

\(e\) Different doses of NOS inhibitor. Indeed, at successively greater NOS inhibitor doses, which induced greater magnitudes of pressure elevation, ET receptor antagonist caused increasingly larger percent inhibitions of NOS inhibitor-elevated pressure ([@B32]; [@B13]; [@B6]). That is, the relative ratio of the ET-1-dependent to -independent components of the NOS inhibitor-elevated pressure increased with NOS inhibitor dose and also, therefore, with greater amounts of NOS inhibitor-induced pressure elevation ([@B32]; [@B13]; [@B6]). The dose range of the NOS inhibitor, *N*^ω^-nitro-[L]{.smallcaps}-arginine methyl ester (L-NAME, intravenous bolus), in rat was 0.1--3 mg/kg ([@B32]) and 0.125--2 mg/kg ([@B13]), with maximal increased mean arterial pressure achieved at 1 mg/kg. In dog, the dose range of L-NAME (intravenous bolus) was 0.3--10 mg/kg, with the increase in mean arterial pressure achieved at 10 mg/kg only slightly greater than that at 3 mg/kg ([@B6]).

However, similar maximally effective (pressure elevation) doses of L-NAME established in these studies ([@B32]; [@B13]; [@B6]) were also used in a number of studies, i.e., 2 mg/kg ([@B9]) and 10 mg/kg ([@B30]; [@B18]; [@B14]; [@B22]). Furthermore, while other studies used NOS inhibitors other than L-NAME, i.e., *N*^ω^-monomethyl-[L]{.smallcaps}-arginine (L-NMMA) and *N*^ω^-nitro-[L]{.smallcaps}-arginine (L-NNA), these inhibitors were used at similar or even greater doses than in the studies with L-NAME. Specifically, L-NMMA was administered at 30 mg/kg ([@B15]) and 6 mg/kg followed by 3.6 mg/kg/h infusion (in human; [@B33]), and L-NNA was administered at 4 mg/kg ([@B10]), 5 mg/kg ([@B19]), 10 mg/kg ([@B16]), 20 mg/kg ([@B25]; [@B11]), and 5 mg/kg followed by 5 mg/kg/h infusion ([@B21]).

It should be noted that NOS inhibitor was also infused in the absence of prior intravenous bolus. In animals, L-NAME was infused over the dose range of 3--12 mg/kg/h ([@B28]; [@B35]; [@B26]; [@B36]; [@B17]). In contrast to another human study ([@B33], see above), only a relatively low dose of L-NAME was infused, i.e., 0.18 mg/kg/h ([@B27]). Finally, in two rat studies, L-NAME was injected i.p. at 100 mg/kg ([@B3]; [@B8]).

### ET~**B**~ receptor antagonist

The effect of ET~B~ receptor antagonist on the NOS inhibitor-elevated pressure was difficult to evaluate in some studies due to the increased basal pressure ([@B18]; [@B36]; **Figure [1](#F1){ref-type="fig"}**). In these studies, ET~B~ receptor antagonist failed to alter the NOS inhibitor-elevated pressure ([@B36]) or the pressure was possibly increased ([@B18]). In the one study in which ET~B~ receptor antagonist did not alter basal arterial pressure, NOS inhibitor-elevated pressure remained unaltered by the ET~B~ receptor antagonist ([@B22]).

ET-1 AND BIG ET-1 PLASMA LEVELS
-------------------------------

ET-1 plasma levels were inconsistently elevated by NOS inhibitors. Although elevated ET-1 plasma levels were detected following acute challenge with NOS inhibitor in the dog, human, and rat, the increases were of relatively small magnitude ([@B32]; [@B1]; [@B13]; [@B10]). ET-1 plasma levels were not elevated following NOS inhibitor in stroke-prone spontaneously hypertensive rat, rabbit, and conscious sheep ([@B37]; [@B18]; [@B14]). Also, in the human, while maximal ET-1 plasma levels and arterial pressure were observed 20 min and 10 min (initial recording) post NOS inhibitor, respectively, ET-1 plasma levels were not elevated at 30 min post NOS inhibitor even though the pressure remained elevated ([@B1]).

A limited temporal association between elevated ET-1 plasma levels and NOS inhibitor-elevated arterial pressure was observed in the dog since both elevated ET-1 plasma levels and elevated pressure were observed after 15 min infusion with NOS inhibitor ([@B10]). On the other hand, ETR-P1/fl peptide, an ET~A~ receptor antagonist which purportedly also binds ET-1 ([@B5], [@B4]), completely prevented the increased ET-1 plasma levels but did not significantly reduce and only partially reduced NOS inhibitor-elevated pressure and -elevated peripheral vascular resistance, respectively ([@B10]).

The inability to detect NOS inhibitor-elevated ET-1 plasma levels may be due to clearance of plasma ET-1 by ET~B~ receptors located in the lung and other tissues ([@B12]). However, elevated ET-1 plasma levels were still not detected in the rabbit when ET~B~ receptor antagonist was added 10 min after bolus injection of NOS inhibitor ([@B18]). Although, the detection of elevated ET-1 plasma levels in response to NOS inhibitor in stroke-prone spontaneously hypertensive rat was dependent on the presence of an ET~A/B~ receptor antagonist ([@B14]). An additional factor that undoubtedly complicates the detection of elevated plasma ET-1 levels is plasma dilution.

Big ET-1 plasma levels were elevated by intravenous bolus NOS inhibitor in the rabbit ([@B18]). The increase was transient, with elevated levels at 1 and 2 min which returned to basal by 10 min ([@B18]). Interestingly, ET~B~ receptor antagonist also elevated big ET-1 levels and, furthermore, NOS inhibitor prevented this elevation ([@B18]).

TIME COURSE OF ELEVATED PRESSURE BY ACUTE NOS INHIBITOR
=======================================================

The differential effects of ET receptor antagonist and phosphoramidon on the phases of NOS inhibitor-elevated pressure suggest a dependency on different pools of ET-1 (see Conclusion/speculations). That is, (a) NOS inhibitor elicited an initial rapid (minutes) pressure elevation followed by a plateau phase, as demonstrated with intravenous bolus NOS inhibitor in mouse ([@B9]), rat ([@B15]; [@B14]), and rabbit ([@B18]), and intraperitoneal NOS inhibitor in rat ([@B3]) and (b) ET receptor antagonist reduced both the initial rapid phase and plateau phase of NOS inhibitor-elevated pressure in rat and rabbit ([@B3]; [@B15]; [@B18]). It should be noted, however, that ET~A/B~ receptor antagonist did not reduce the initial rapid phase in the stroke-prone spontaneously hypertensive rat ([@B14]). Whether the underlying effects of stroke/hypertension resulted in the apparent ET-1 independence of the initial phase ([@B14]) should be considered.

Phosphoramidon (10 mg/kg), in contrast to ET receptor antagonist, did not reduce the rapid phase of NOS-elevated pressure in rabbit ([@B18]). However, the plateau phase of the pressure elevation was inhibited by phosphoramidon ([@B18]).

INFLUENCE OF PRESSURE/OTHER PRESSOR PATHWAYS
============================================

NOS inhibitor-elevated pressure in rat was decreased by combined vasopressin~1/2~, angiotensin~1~, and alpha adrenergic receptor antagonists ([@B3]), ganglionic blockade and pithing ([@B32]), and epidural lidocaine anesthesia ([@B6]), while the magnitude of the ET-1-dependent component of the NOS inhibitor-elevated pressure remained unaltered. Indeed, the absolute mmHg reduced by ET receptor antagonist following ganglionic blockade and pithing was greater than in untreated rats ([@B32]). Also of possible relevance is that ET receptor antagonist did not decrease the elevated arterial pressure due to angiotensin in rabbit ([@B18]) and phenylephrine in rat ([@B32]).

The effect of ET receptor antagonist challenge prior versus during NOS inhibitor-elevated pressure also reflects differences in pressure elevation. Although numerous studies investigated the effects of ET receptor antagonist on the NOS inhibitor-elevated pressure by antagonist addition prior to NOS inhibitor ([@B32]; [@B3]; [@B13]; [@B16]; [@B14]; [@B19]; [@B27]; [@B22]; [@B17]; [@B21]; [@B6]; [@B10]; [@B9]; **Figure [1](#F1){ref-type="fig"}**), or during the NOS inhibitor plateau pressure elevation ([@B35]; [@B3]; [@B15]; [@B26]; [@B36]; [@B22]; [@B33]; [@B25]; [@B11]; **Figure [1](#F1){ref-type="fig"}**), only two studies performed both protocols ([@B3]; [@B22]). Similar magnitudes of reduction of the NOS inhibitor-elevated pressure were observed in rat when ET receptor antagonist was added prior to NOS inhibitor as compared to during the NOS inhibitor plateau pressure elevation ([@B3]). Furthermore, similar time periods (\~5 min) were required to achieve plateau pressure elevation following ET receptor antagonist addition prior to NOS inhibitor and for ET receptor antagonist to reverse the NOS inhibitor plateau elevation and elicit a lower level of plateau pressure elevation ([@B3]). While another rat study also determined the effects of ET receptor antagonist challenge prior to NOS inhibitor and during the elevated pressure due to NOS inhibitor, quantification of the reductions of the NOS inhibitor-elevated pressure was difficult due to the lowered basal arterial pressure by the ET receptor antagonist ([@B22]).

INCREASED VASCULAR RESISTANCE AND ET RECEPTOR ANTAGONIST
========================================================

While there is considerable evidence that ET receptor antagonist inhibits the increased peripheral vascular resistance due to NOS inhibitor, studies in which the effects of ET receptor antagonist on both the increased peripheral vascular resistance and on blood pressure have not been surmized. Indeed, ET receptor antagonist caused similar percent reductions of NOS inhibitor-elevated pressure and -elevated peripheral vascular resistance in anesthetized rat ([@B35]) and dog ([@B17]). Also in anesthetized dog, ET receptor antagonist reduced NOS inhibitor-elevated peripheral vascular resistance by as much as 60% ([@B10]). Although in this study ([@B10]) the ET receptor antagonist reduction of the NOS inhibitor-elevated pressure was not statistically significant, this lack of significance may be attributed to the relatively large variability in the pressure measurements.

In possible contrast, in conscious dog, ET receptor antagonist decreased NOS inhibitor-elevated pressure by 67% while, unexpectedly, peripheral vascular resistance was not decreased ([@B6]). While the lack of ET receptor antagonist reduction of the NOS inhibitor-elevated peripheral vascular resistance might suggest the involvement of other hemodynamic factors, an effect on NOS inhibitor-induced decreased cardiac output was apparently not observed ([@B6]).

Interestingly, in this same study ([@B6]) but with dogs subjected to epidural anesthesia, ET receptor antagonist decreased the NOS inhibitor-elevated peripheral vascular resistance and the elevated arterial pressure by 50 and 67%, respectively.

CONCLUSION/SPECULATIONS
=======================

As illustrated in the model of **Figure [2](#F2){ref-type="fig"}**, considerable evidence from studies on the effects of phosphoramidon and ET~A~ and ET~A~/ET~A/B~ receptor antagonists on the elevated pressure due to acute challenge with NOS inhibitor demonstrates that ET-1 mediates a component of the pressure elevation. This component demonstrates marked variability which cannot be accounted for by numerous experimental parameters. Also, the component is independent of other NOS inhibitor-elevated pressure pathways (see also [@B23]; [@B7]). Thus, the variation reflects the overall capacity of the NO-regulated, ET-1-mediated pathways to elevate pressure.

![**ET-1-dependent and -independent components of the elevated arterial pressure due to acute NOS inhibitor.** **(A)** Dose-response: NOS inhibitor (NOS-I) dose and ET-1-independent (dashed line) and -dependent pressure elevation (solid line). **(B)** ET-1 pools: ET-1-dependent component (solid line) consists of an initial rapid and a subsequent plateau increase in pressure (rightward upward and rightward downward slanted lines, respectively), which reflect dependencies on stored ET-1 and *de novo* synthesized ET-1 pools, respectively. ET-1-independent pressure elevation is indicated by the dashed line. Squiggled vertical lines indicate varied magnitudes of ET-1-independent and -dependent components of pressure elevation. See text for further details.](fphar-05-00057-g002){#F2}

Another characteristic of the ET-1-dependent component of the NOS inhibitor-elevated pressure is the apparent dependency of the pressure elevation on different ET-1 pools, i.e., the initial rapid phase and plateau phase of pressure elevation may reflect ET-1 release from stored ET-1 and from *de novo* synthesized ET-1, respectively. It is important to note that these observations provide at least indirect *in vivo* evidence for the involvement of increased ET-1 release in the NOS inhibitor-elevation of arterial pressure. Indeed, direct support for increased ET-1 release by NOS inhibitor as evidenced by elevated plasma ET-1 levels is inconsistent, presumably due to ET-1 clearance and plasma dilution. Thus, while enhanced ET-1 contraction due to removal of NO-mediated vasodilatation undoubtedly contributes to the NOS inhibitor-elevated arterial pressure ([@B24]; [@B39]; [@B20]), ET-1 release represents a contributing factor.

With respect to the mechanism underlying the increased ET-1 release, several lines of evidence suggest that the release is not the result of elevated pressure. Indeed, this conclusion also infers that the component of the NOS inhibitor-elevated pressure attributed to reversal of NO relaxation of smooth muscle ([@B3]) also does not trigger ET-1 release. First, lowered basal pressure due to inhibition of a number of pressor pathways did not decrease the magnitude of the ET-1-dependent component of NOS inhibitor-elevated pressure. Second, ET receptor antagonist caused a similar magnitude of inhibition of the NOS inhibitor-elevated pressure when added prior to NOS inhibitor addition and during the plateau pressure elevation. Third, ET receptor antagonist did not reduce the pressure elevated by angiotensin II and phenylephrine ([@B32]; [@B18]). It should also be considered; however, that the lack of effect of ET receptor antagonist on pressure due to these agents ([@B32]; [@B18]) resulted from increased NO formation, which prevented ET-1 release. It would be of interest to investigate, therefore, whether ET receptor antagonist reduction of NOS inhibitor-elevated pressure is increased in the presence of a pressor agent other than ET-1.

In any case, the mechanism whereby *de novo* synthesized ET-1 is released may be due to reversal of NO inhibition of the conversion of big ET-1 to ET-1, since NOS inhibitor elevated big ET-1 plasma levels ([@B18]). Furthermore, this regulatory pathway appears to be shared by ET~B~ receptor-mediated formation of NO, since NOS inhibitor prevented the ET~B~ receptor-mediated increase in big ET-1 plasma levels ([@B18]).

THERAPEUTIC IMPLICATIONS
========================

Based on the independence of the ET-1-dependent component of the elevated pressure due to acute challenge with NOS inhibitor from other pressor systems, it is reasonable to conclude that the ET-1-dependent effects of NOS inhibition specifically reflect NO-ET-1 regulatory pathways. Thus, for example, ET receptor antagonist partial prevention of the acute NOS inhibitor-elevated pressure in high-salt diet induced hypertension in bradykinin~2~ receptor knockout but not wild type mouse suggests an enhancement of the NO-ET-1 regulatory pathway ([@B9]; **Figure [1](#F1){ref-type="fig"}**). Also, acute hypoxia may depress the NO-ET-1 regulatory pathway since hypoxia lowered the magnitude of the NOS inhibitor-elevated, ET-1-dependent pressure from 61 to 40% ([@B21]; **Figure [1](#F1){ref-type="fig"}**).

Additionally, at least based on a limited number of studies in which ET~A~ and ET~A~/ET~A/B~ receptor antagonists were compared head-to-head, the elevated pressure due to NOS inhibitor appears to result from ET-1 activation of smooth muscle ET~A~ receptors. Thus, ET~A~ receptor antagonist should effectively reduce the increased blood pressure that may involve, e.g., endothelial ET~B~ receptor dysfunction. On the other hand, an ET~A/B~ receptor antagonist may possess greater therapeutic efficacy in pathologies in which ET~B~ receptor activation contributes significantly to the pressure elevation.

It should also be noted that the endogenous NOS inhibitor, asymmetric dimethylarginine, has been implicated in numerous vascular pathologies ([@B2]; [@B34]; [@B38]). Moreover, these pathologies include conditions in which plasma asymmetric dimethylarginine levels rise relatively rapidly, such as pre-eclampsia and acute stroke ([@B2]; [@B34]; [@B38]). Thus, the *in vivo* effects of acute NOS inhibitor are highly relevant with respect to investigations into the altered NO-ET-1 regulatory pathways in these pathologies.

Finally, based on the observations that the ET-1-dependent component of the NOS inhibitor-elevated pressure increase with NOS inhibitor dose ([@B32]; [@B13]; [@B6]), it is of interest to speculate that ET receptor antagonist treatment of pathologies associated with NO dysregulation is more effective under conditions of greater dysregulation. Whether this greater efficacy reflects increased relative involvement of ET-1 release or enhanced ET-1-induced vasoconstriction requires additional understanding of the mechanism whereby NO regulates these pathways.
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